Patents by Inventor Seema K. Tiwari-Woodruff

Seema K. Tiwari-Woodruff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES
    Publication number: 20230357161
    Abstract: 4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.
    Type: Application
    Filed: April 12, 2023
    Publication date: November 9, 2023
    Inventors: John A. Katzenellenbogen, Seema K. Tiwari-Woodruff, Sung Hoon Kim, Benita Katzenellenbogen
  • Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
    Patent number: 11673866
    Abstract: 4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 13, 2023
    Assignees: The Board of Trustees of the University of Illinois, The Regents of the University of California
    Inventors: John A. Katzenellenbogen, Seema K. Tiwari-Woodruff, Sung Hoon Kim, Benita Katzenellenbogen
  • ESTROGEN RECEPTOR BETA LIGANDS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMYELINATING, INFLAMMATORY AND NEURODEGENERATIVE DISEASES
    Publication number: 20210230121
    Abstract: 4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 29, 2021
    Inventors: John A. Katzenellenbogen, Seema K. Tiwari-Woodruff, Sung Hoon Kim, Benita Katzenellenbogen
  • Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
    Publication number: 20120282222
    Abstract: This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and/or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair.
    Type: Application
    Filed: July 8, 2010
    Publication date: November 8, 2012
    Inventors: Rhonda R. Voskuhl, Seema K. Tiwari-Woodruff
  • Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
    Publication number: 20110256096
    Abstract: This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and/or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair.
    Type: Application
    Filed: July 8, 2010
    Publication date: October 20, 2011
    Inventors: Rhonda R. Voskuhl, Seema K. Tiwari-Woodruff